Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Rating of “Hold” from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned a consensus rating of “Hold” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $6.75.

A number of analysts recently commented on INO shares. HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $6.00 target price (up from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. UBS Group reaffirmed an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday, December 29th. Finally, Citigroup restated a “market outperform” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, November 4th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in Inovio Pharmaceuticals by 1.3% in the fourth quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock worth $5,773,000 after purchasing an additional 42,146 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Inovio Pharmaceuticals by 35.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after buying an additional 703,727 shares during the period. Boxer Capital Management LLC bought a new position in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $5,382,000. Millennium Management LLC lifted its position in Inovio Pharmaceuticals by 468.7% during the 3rd quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock valued at $4,616,000 after acquiring an additional 1,625,653 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Inovio Pharmaceuticals by 40.7% during the fourth quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company’s stock worth $1,340,000 after acquiring an additional 222,609 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Stock Performance

NASDAQ INO opened at $1.67 on Thursday. The stock has a market cap of $111.44 million, a P/E ratio of -0.64 and a beta of 1.72. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $2.98. The stock has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $2.05.

More Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Negative Sentiment: Multiple plaintiff law firms are soliciting Inovio investors about a class action covering purchases between Oct. 10, 2023 and Dec. 26, 2025 and warning of an April 7, 2026 lead‑plaintiff deadline. These notices increase the likelihood of consolidated litigation and potential legal exposure. Rosen Law Firm notice
• Negative Sentiment: The Gross Law Firm announced the filing of a securities class action on behalf of Inovio shareholders, increasing the number of firms pursuing claims and the public attention on alleged company misstatements. Gross Law Firm article
• Negative Sentiment: Law Offices of Frank R. Cruz is soliciting inquiries from INO shareholders about securities fraud claims—another firm publicizing potential litigation and recruiting lead plaintiffs. Frank R. Cruz notice
• Negative Sentiment: Levi & Korsinsky issued a class action notice with the same class period and April 7, 2026 deadline, emphasizing potential recoveries for affected shareholders. Levi & Korsinsky release
• Negative Sentiment: Pomerantz filed a class action naming Inovio and certain officers in the Eastern District of Pennsylvania (docket 26-cv-00803), representing a formal lawsuit rather than only a notice. This is a direct adverse legal development. Pomerantz filing
• Negative Sentiment: The Schall Law Firm reminded investors of the suit and the April 7 deadline, signaling competition among firms to lead the litigation which can affect recovery dynamics and publicity. Schall Law Firm notice
• Negative Sentiment: Glancy Prongay Wolke & Rotter and additional firms have also published notices of the filed securities fraud action, underscoring broad legal attention that could lead to defense costs, settlements or judgment risk. Glancy notice
• Negative Sentiment: Additional Rosen and PR Newswire notices reiterate the class period and April 7 deadline, increasing investor awareness and the chance of more filings or consolidation motions. Rosen/PR Newswire release

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.